Celldex Therapeutics Announces Upcoming Presentation at Oppenheimer Healthcare Conference

Celldex Therapeutics Announces Upcoming Presentation at Oppenheimer Healthcare Conference

<0> Celldex Therapeutics, Inc.Sarah Cavanaugh, 781-433-3161Vice President of IR & Corp CommorBMC CommunicationsBrad Miles, 646-513-3125 </0>

(NASDAQ: CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, is scheduled to present a corporate overview at the Oppenheimer 23rd Annual Healthcare Conference on Wednesday, December 12, 2012 at 10:00 am ET at the Waldorf=Astoria in New York City.

A of the presentation will be available online on the “Events & Presentations” page of the “Investors & Media” section of the Celldex website. A replay of the presentation will be available for 30 days following the event.

Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, please visit .

Suggested Articles

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.

The series A sets ex-Gilead R&D chief Norbert Bischofberger up to advance efforts to hit historically undruggable targets.